Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers

Solid cancers are dependent on angiogenesis for sustenance. The FDA approval of Bevacizumab in 2004 inspired many scientists to develop more inhibitors of angiogenesis. Although several monoclonal antibodies (mAbs) are being administered to successfully combat various pathologies, the complexity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Arezumand, Roghaye, Alibakhshi, Abbas, Ranjbari, Javad, Ramazani, Ali, Muyldermans, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727022/
https://www.ncbi.nlm.nih.gov/pubmed/29276515
http://dx.doi.org/10.3389/fimmu.2017.01746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727022/
https://www.ncbi.nlm.nih.gov/pubmed/29276515
http://dx.doi.org/10.3389/fimmu.2017.01746

Ejemplares similares